Papp KA, et al. - In a double-blinded, placebo-controlled phase 2b study, the effectiveness and safety of bimekizumab (a monoclonal antibody that potently and selectively neutralizes IL-17A and IL-17F) were evaluated in patients with moderate-to-severe plaque psoriasis. Bimekizumab led to dual neutralization of IL-17A and IL-17F, thereby providing rapid and substantial clinical improvements in patients with psoriasis, without any unexpected or dose-related safety findings. Compared to patients receiving placebo, more bimekizumab-treated patients achieved PASI100. Authors noted that 61% of bimekizumab-treated patients and 36% placebo-treated patients reported treatment-emergent adverse event(TEAEs).